Lantheus completed the sale of its SPECT business to SHINE Technologies in January 2026, transferring SPECT diagnostic agents and related operations. The company closed the acquisition of Life Molecular Imaging in July 2025 and repurchased $100M of common stock in Q3. Updated FY2025 guidance shows $1.49B–$1.51B revenue and $5.50–$5.65 adjusted EPS.
Cyborg Score Rationale
Lantheus demonstrates strong market positioning as a leading radiopharmaceutical company with robust revenue growth and strategic portfolio optimization through divestitures and acquisitions. However, recent leadership transition and competitive pressures create near-term execution risk.
Top Insights
Lantheus divested its SPECT business in January 2026 to concentrate on commercial PET radiodiagnostics and microbubbles while advancing its radiopharmaceutical pipeline.
FDA PDUFA target action dates were set for a new piflufolastat F 18 formulation (Mar 6, 2026), LNTH-2501 Ga 68 kit (Mar 29, 2026) and MK-6240 (Aug 13, 2026).
In 2024, Lantheus Holdings's revenue was $1.53 billion, an increase of 18.32% compared to the previous year's $1.30 billion.
CEO Brian Markison retired effective Dec 31, 2025, and Chairperson Mary Anne Heino became Executive Chairperson and interim CEO.
Named Competitors
Novartis — Radiopharmaceutical oncology and molecular imaging
Siemens Healthineers — Diagnostic imaging and nuclear medicine systems
GE HealthCare — Medical imaging and diagnostic equipment
Curium Pharma — Radiopharmaceutical products and imaging solutions
Recent Developments
(January 2026) SPECT business sale to SHINE Technologies completed
(December 2025) CEO leadership transition - Brian Markison retired, Mary Anne Heino named interim CEO